References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
- Australian Institute of Health and Welfare. Cancer data in Australia: Canberra: Australian Institute of Health and Welfare; 2020 [cited 2020 Apr]. Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia
- Cancer Council Australia Lung Cancer Prevention and Diagnosis Guidelines Working Party. Clinical practice guidelines for the prevention and diagnosis of lung cancer: Sydney: Cancer Council Australia; 2020 [cited 2020 Apr]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Lung_cancer/Prevention_and_diagnosis
- Cancer Council Australia Lung Cancer Prevention and Diagnosis Guidelines Working Party. Clinical practice guidelines for the treatment of lung cancer: Sydney: Cancer Council Australia; 2020 [cited 2020 Apr]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Lung_cancer
- John T, Bowden JJ, Clarke S, et al. Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia Pac J Clin Oncol. 2017 Aug;13(4):296–303.
- Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113–125.
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41–50.
- Pharmaceutical Benefits Advisory Committee. Osimertinib Public Summary Document-July 2019 PBAC meeting 2019 [cited 2020 Apr]. Available from: https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-07/files/osimertinib-psd-july-2019.pdf
- Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Med Decis Making. 2012 Sep-Oct;32(5):690–700.
- Woods B, Sideris E, Palmer S, et al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review 2017 [cited 2020 Apr]. Available from: http://nicedsu.org.uk/wp-content/uploads/2017/06/Partitioned-Survival-Analysis-final-report.pdf
- Pharmaceutical Benefits Advisory Committee. Gefitinib public summary document-july 2013 PBAC meeting 2013 [cited 2020 Apr]. Available from: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/gefitinib
- Pharmaceutical Benefits Advisory Committee. Erlotinib Public Summary Document-July 2013 PBAC meeting 2013 [cited 2020 Apr]. Available from: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/erlotinib
- Pharmaceutical Benefits Advisory Committee. Afatinib Public Summary Document-July 2013 PBAC meeting 2013 [cited 2020 Apr]. Available from: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/afatinib-first-line
- Pharmaceutical Benefits Advisory Committee. Guidelines for preparing a submission to the pharmaceutical benefits advisory committee (version 5.0) 2016 [cited 2020 Apr]. Available from: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf
- Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011 Oct;10(11):139.
- Jackson CH. flexsurv: A platform for parametric survival modeling in R. J Stat Softw. 2016 May;12:70.
- Department of Health. MBS Online Medicare Benefits Schedule 2020 [cited 2020 Apr]. Available from: http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home
- Independent Hospital Pricing Authority. National hospital cost data collection, ar-drg cost weight tables V8.0x, round 21 (Financial year 2016-17) 2019 [cited 2020 Apr]. Available from: https://www.ihpa.gov.au/publications/national-hospital-cost-data-collection-ar-drg-cost-weight-tables-v80x-round-21
- Goldsbury DE, Yap S, Weber MF, et al. Health services costs for cancer care in Australia: estimates from the 45 and up study. PLoS One. 2018;13(7):e0201552.
- Latimer N NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data 2013 [cited 2020 Apr]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf
- Ding PN, Roberts TL, Chua W, et al. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney local health district. Intern Med J. 2017 Dec;47(12):1405–1411.
- Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct;29(Suppl 4):iv192–iv237.
- Australian Institute of Health Welfare. Health expenditure australia 2017–18: canberra: Australian institute of health and welfare; 2019 [cited 2020 Apr]. Available from: https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2017-18/data
- Department of Health. The Pharmaceutical Benefits Scheme 2020 [cited 2020 Apr]. Available from: https://www.pbs.gov.au/pbs/home
- Leighl NB, Karaseva N, Nakagawa K, et al. Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer. 2020;125:49–57.
- Labbe C, Leung Y, Silva Lemes JG, et al. Real-world EQ5D health utility scores for patients with metastatic lung cancer by molecular alteration and response to therapy. Clin Lung Cancer. 2017 Jul;18(4):388–395 e4.
- Wang S, Gum D, Merlin T. Comparing the ICERs in Medicine reimbursement submissions to NICE and PBAC-does the presence of an explicit threshold affect the ICER proposed? Value Health. 2018 Aug;21(8):938–943.
- Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629–640.
- Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011 Jun 10;29(17):2439–2442.
- Aziz MIA, Foo WYX, Toh CK, et al. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. J Med Econ. 2020;4:1.
- Ezeife DA, Kirk V, Chew DS, et al. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. Lung Cancer. 2018;125:1–7.
- Holleman MS, Al MJ, Zaim R, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020 Feb;21(1):153–164.
- Aguiar PN Jr., Haaland B, Park W, et al. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. JAMA Oncol. 2018 Aug 1;4(8):1080–1084.
- Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, et al. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res. 2019 8;Aug(11):853–863.
- Wu B, Gu X, Zhang Q, et al. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019 Mar;24(3):349–357.
- Cai H, Zhang L, Li N, et al. Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small cell lung cancer in China. Clin Ther. 2019 Feb;41(2):280–290.